Clinical Trial · NCT02392429

FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia

Overview

This phase II trial studies fluorothymidine F 18 (FLT) positron emission tomography (PET)/computed tomography (CT) in measuring response in patients with previously untreated acute myeloid leukemia. FLT is a radioactive substance that may "light up" where cancer is in the body. FLT is injected into the blood and builds up in cells that are dividing, including cancer cells. Diagnostic procedures, such as PET/CT, may help measure a patient's response to earlier treatment.

Sponsor

National Cancer Institute

Phase

Phase 2

Contacts

Robert Jeraj (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT02392429

Drug / Compound

FLT

Isotope(s):

Target(s):

cytosolic thymidine kinase 1

Ligand Class: Small Molecules

Eligibility

Inclusion

* Age ≥ 18 years
Patients must not have acute promyelocytic leukemia (APL) and must not have evidence of t(15;17)(q22;q21)
Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3 (restricted to ECOG performance status \[PS\] 0-2 if age \> 70 years)
Patients must have left ventricular ejection fraction (LVEF) \> 45% or within institutional normal limits
Patients must have previously untreated AML and be candidates for intensive induction chemotherapy; patients are allowed to have had prior hydroxyurea

Exclusion

Exclusion criteria not yet provided.